Navigation

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy) [ID465]

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

Status: History
Expected date of issue: June 2012
Referral date: May 2011
Process: STA
Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Matthew Dyer
Communications manager: Alice Law
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 23 September 2011
1st appraisal committee meeting: 05 January 2012
2nd appraisal committee meeting 03 April 2012
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

 

Manufacturers/sponsors

  • Janssen (abiraterone)

Patient/carer groups

  • Macmillan Cancer Support
  • PCaSO – Prostate Cancer Network
  • Prostate Cancer Charity
  • Prostate Cancer Support Federation

Professional groups

  • British Association of Urological Surgeons
  • British Uro-Oncology Group
  • Cancer Research UK
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Physicians
  • United Kingdom Clinical Pharmacy Association
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • NHS Hertfordshire
  • NHS Bradford and Airedale
  • Welsh Government

 

 

 

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturers

Relevant research groups

  • MRC Clinical Trials Unit
  • Prostate Action
  • Evidence Review Group
  • Warwick Evidence
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • Tbc

Top


 

Key documents

This page was last updated: 11 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.